About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
IONS - Ionis Pharmaceutical...| Previous Close | $51.27 | Open | $51.66 |
| Volume | 918.7K | Market Cap | 7.169B |
| Yield | Last Dividend |
| Ionis establishes new grant program to a... | 03/01/21 |
| CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program... | |
| Ionis reports fourth quarter and full ye... | 02/24/21 |
| CARLSBAD, Calif., Feb. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter... | |
| Earnings Scheduled For February 24, 2021 | 02/24/21 |
| Companies Reporting Before The Bell ??? Pinnacle West Capital (NYSE: PNW ) is expected to report quarterly earnings at $0.04 per share on revenue of $... | |
| Ionis to hold 2020 financial results web... | 02/11/21 |
| /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. E... | |
| DelveInsight Analysts Expect Beta-Thalas... | 02/08/21 |
| LAS VEGAS , Feb. 8, 2021 /PRNewswire/ -- DelveInsight's Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta T... | |
| The Daily Biotech Pulse: Sorrento, Immut... | 01/27/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Ale... | |
| The Daily Biotech Pulse: Novartis Misses... | 01/26/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abb... | |
| Aro Biotherapeutics Announces $88 Millio... | 01/05/21 |
| PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today ann... | |
| Amyotrophic Lateral Sclerosis (ALS) Mark... | 12/14/20 |
| In Amyotrophic Lateral Sclerosis (ALS) Market report, a systematic investment analysis has been performed which forecasts impending opportunities for ... | |
| Insider Selling: Ionis Pharmaceuticals, ... | 12/12/20 |
| Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the stock in a transaction dated Monday, December 7th. The ... | |
| Global Cytomegalovirus Retinitis Market ... | 12/11/20 |
| Data Bridge Market Research has recently added a concise research on the Cytomegalovirus Retinitis Market to depict valuable insights related to signi... | |
| Plasma Protease C1-inhibitor Treatment M... | 12/11/20 |
| The research report Plasma Protease C1-inhibitor Treatment Market Analysis 2020 provides an estimate of the market size from 2020 to 2026 in terms of ... | |
| Amyotrophic Lateral Sclerosis (ALS) Mark... | 12/10/20 |
| In Amyotrophic Lateral Sclerosis (ALS) Market report, a systematic investment analysis has been performed which forecasts impending opportunities for ... | |
| Ionis highlights achievements, commercia... | 12/08/20 |
| CARLSBAD, Calif., Dec. 8, 2020 /PRNewswire/ -- At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's sig... | |
| Ionis to participate in virtual fireside... | 12/02/20 |
| CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that ... | |
| U.S. Transthyretin Amyloidosis Treatment... | 11/17/20 |
| Industrial Growth Forecast Report U.S. Transthyretin Amyloidosis Treatment Market 2020-2027: The Global U.S. Transthyretin Amyloidosis Treatment Marke... | |
| Promising new data for Ionis' antisense ... | 11/13/20 |
| CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigationa... | |
| Ionis' pioneering antisense technology t... | 11/12/20 |
| CARLSBAD, Calif., Nov. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and... | |
| Ionis' antisense technology to be featur... | 11/10/20 |
| CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will hig... | |
| Ionis and Akcea Recognize FCS Awareness ... | 11/06/20 |
| BOSTON & CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize ... | |
| Ionis reports third quarter 2020 financi... | 11/04/20 |
| /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business high... | |
| Amyotrophic Lateral Sclerosis Treatment ... | 11/02/20 |
| The Amyotrophic Lateral Sclerosis Treatment Market report identifies and analyses the up-and-coming trends along with major drivers, challenges and op... | |
| Ionis and Akcea win prestigious Prix Gal... | 10/30/20 |
| BOSTON and CARLSBAD, Calif., Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeut... | |
| Ionis Pharmaceuticals, Inc. (NASDAQ:IONS... | 10/22/20 |
| Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III sold 2,889 shares of the company???s stock in a transaction on Tuesday, October 20... | |
| Bulbospinal Muscular Atrophy Drugs Marke... | 10/19/20 |
| Global Bulbospinal Muscular Atrophy Drugs Market is growing at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base... | |
| Atherosclerosis Market Shows Strong Grow... | 10/16/20 |
| Atherosclerosis Market analysis report is a professional yet exhaustive study on the current state for the market. The market study of Atherosclerosis... | |
| Ionis antisense medicine being evaluated... | 10/15/20 |
| CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that... | |
| RNA Therapeutics Market 2020 Analysis, S... | 10/14/20 |
| The winning RNA Therapeutics Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chi... | |
| Ionis' inhaled antisense medicine demons... | 10/13/20 |
| CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that... | |
| Ionis Pharmaceuticals completes acquisit... | 10/12/20 |
| /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of A... | |
| Sell rating | 02/25/21 |
| Morgan Stanley maintains Underweight rating and raises Price Target from $49.00 to $50.00 | |
| Date | 2021-02-24 (BMO) | Est. (EPS/Rev.) | $0.28/ 274.48M |
| Actual (EPS/Rev.) | $0.81/ $290.00 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
